University of Rochester awarded patent for class of drugs known as cox-2 inhibitors

April 11, 2000

The University of Rochester announced today that it has been awarded a pioneering patent for the use of the entire class of drugs known as cox-2 inhibitors, the popular new medications that have been heralded as "super aspirin" for their remarkable ability to ease pain and inflammation without causing side effects such as stomach pain, bleeding, or ulcers. Many experts believe that the drugs will replace aspirin and ibuprofen in the next century.

The class of drugs, which includes the blockbuster arthritis medication Celebrex, have become top-sellers since they were introduced last year. Doctors prescribed Celebrex to 6.4 million patients in 1999, pushing its first-year sales to $1.5 billion. Last year Celebrex eclipsed the anti-impotence medication Viagra as the fastest-selling new drug in history.

The patent awarded yesterday entitles the University of Rochester to royalties on the sale of all cox-2 inhibitors. Shortly after the patent was awarded, attorneys representing the University of Rochester filed an infringement suit in federal court against Searle and Pfizer, the pharmaceutical companies which jointly market Celebrex.

"We've filed a lawsuit against Searle and Pfizer to ensure that our legal rights are preserved, though we intend to begin discussions with both companies in an effort to negotiate licensing agreements," said Terrance O'Grady, an attorney for the University.

Over the 17-year life of the patent, royalty payments could yield the University royalties in the billions of dollars, making it the most lucrative pharmaceutical patent in history.

The new class of drugs was developed after researchers at the University of Rochester discovered the gene in humans that is responsible for producing an enzyme called cox-2 and revealed the enzyme's role in causing inflammation within individual cells. The discovery, made more than a decade ago, set in motion a worldwide race among pharmaceutical companies to identify drugs that would inhibit the action of the enzyme and, in turn, reduce inflammation and pain.

The University of Rochester research team was led by Donald Young, M.D., a physician and biochemist who for more than three decades has studied the mechanisms by which steroids reduce inflammation and produce other effects in cells.

"This patent recognizes the contributions of Dr. Young, an outstanding scientist who has devoted his career to understanding a problem that afflicts tens of millions of people," said Jay H. Stein, M.D., senior vice president for Health Affairs at the University of Rochester and chief executive officer of the University of Rochester Medical Center.

Young began his scientific career in the 1960s, studying the ways that steroids control the production of protein molecules inside cells. The work led him to question the role of a then-unknown protein that was produced in cells that were becoming cancerous. The protein appeared to be related to an enzyme then known as cyclooxygenase, or cox, made in every cell in the body and whose activity could be blocked by aspirin and other nonsteriodal anti-inflammatory drugs.

Young and two other researchers in his lab, Kerry O'Banion and Virginia Winn, studied the newly discovered protein and identified the gene that produces it. They found that, unlike cox, the production of the new protein could be virtually shut down by administering an anti-inflammatory steroid. This finding led Young to conclude that aspirin and other NSAIDs were effective at controlling inflammation because they were acting on the new protein - which was later named cox-2 - and that the unwanted side effects of gastro-intestinal irritation and bleeding were caused by the NSAIDs' effects on the original cox enzyme, which would later come to be known as cox-1.

Further study of the cox-1 enzyme revealed that its role is not related to inflammation. Rather, it is believed to have many roles - among them, to turn off the secretion of gastric acid in the stomach. Aspirin and other NSAIDs, while effectively blocking cox-2 also block cox-1, resulting in excessive production of stomach acid as well as ulceration and gastrointestinal bleeding. These and other side effects of aspirin and other NSAIDs caused 76,000 people to be hospitalized in 1998 and resulted in 16,500 deaths.

Young and his colleagues at the University of Rochester were the first to demonstrate that production of the cox-2 enzyme is triggered by two kinds of molecular messengers called inflammatory cytokines and growth factors. The team also genetically-engineered two types of cells - one that produces cox-2 but not cox-1, and vice-versa - to enable researchers to identify drugs that inhibit the production of cox-2 without inhibiting the production of cox-1. Several pharmaceutical companies used Young's cells, or similar methods, to develop cox-2 inhibitors.

In addition to the remarkable ability of cox-2 inhibitors to control pain and inflammation, research suggests that the drugs can also prove useful in preventing cancer and Alzheimer's disease. Young's work in 1990 established a link between cox-2 and cancer, an avenue that his lab and now hundreds of others are actively pursuing. Several studies by researchers across the country have demonstrated that the use of cox-2 inhibitors is able to reduce the incidence of colon cancer - and deaths from the disease - by nearly half. Other studies have suggested that the use of cox-2 inhibitors can also be effective in reducing the incidence of Alzheimer's disease by more than 60 percent.
-end-


University of Rochester

Related Aspirin Articles from Brightsurf:

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

What are the risks and benefits of low-dose aspirin?
Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Study: An aspirin a day does not keep dementia at bay
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer's disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Aspirin's health benefits under scrutiny
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.

Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.

Migraine headaches? Consider aspirin for treatment and prevention
Evidence from 13 randomized trials of the treatment of migraine in 4,222 patients and tens of thousands of patients in prevention of recurrent attacks supports the use of high dose aspirin from 900 to 1,300 milligrams to treat acute migraine as well as low dose daily aspirin from 81 to 325 milligrams to prevent recurrent attacks.

Aspirin use after biliary tract cancer diagnosis
Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.

Aspirin may prevent air pollution harms
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function.

Aspirin should not be recommended for healthy people over 70
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease.

Read More: Aspirin News and Aspirin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.